{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Genetic Screening in Amyotrophic Lateral Sclerosis"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "This multicenter, prospective cohort study enrolled 1000 incident ALS patients from 22 ALS centers in France between April 2021 and April 2022. Participants met ALS diagnostic criteria"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the frequency of SOD1 variants and C9orf72 G4C2 repeats, assessed at baseline."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "This multicenter, prospective cohort study enrolled 1000 incident ALS patients from 22 ALS centers in France between April 2021 and April 2022."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "C9orf72 G4C2 repeats were found in 7.6% of patients, while SOD1 variants were present in 1.6%."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT04819555"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 10,
    "max_score": 25
  },
  "model": "gpt-4o"
}